Navigation Links
New indicator found for rapidly progressing form of deadly lung disease
Date:11/10/2010

ANN ARBOR, Mich. A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.

But researchers at the University of Michigan have discovered a receptor in the immune system that may serve as a marker for a rapidly progressing form of the disease, which causes the body to produce excess fibrous tissue in the lungs.

More than just signaling which patients have the more aggressive form of IPF a disease that claims about as many lives each year as breast cancer the researchers hope that targeting the TLR9 receptor may lead to new treatments that could slow or stop the illness' progression. The findings were published in the Nov. 10 issue of Science Translational Medicine.

"This finding has the potential to allow physicians caring for IPF patients to better determine the natural history of disease in individual patients, which could markedly facilitate decision making for the patient and their doctors," says pulmonologist Fernando J. Martinez, M.D., M.S., a professor of internal medicine at the University of Michigan Medical School and one of the study's two senior authors. "Moreover, it opens the potential for unique therapeutic approaches."

There is no known cause, cure, or FDA-approved treatment for IPF, and it remains virtually unknown to the general public, even though it is several times more common than cystic fibrosis and Lou Gehrig's Disease (or ALS), according to the Coalition for Pulmonary Fibrosis. Moreover, IPF only receives a fraction of the funding of those higher profile conditions.

The U-M led research, which drew on expertise from the Departments of Pathology, Internal Medicine and Radiology, found that TLR9, which stands for Toll-like receptor number 9, causes an increase in the growth of fibrotic tissue in the lungs when it recognizes a particular type of DNA frequently found in bacteria and viruses. Higher amounts of TLR9 were found in patients with rapidly progressing IPF than those with slowly progressing IPF.

The researchers also peered into the workings of IPF by transplanting the disease from humans into mice. Those experiments showed a greater fibrotic response to the TLR9-activating DNA using lung cells from patients with rapidly progressing IPF than with cells from people with slowly progressing IPF.

For more than two decades, the National Institutes of Health has funded the U-M group's investigation into the biological basis of IPF as well as novel ways to diagnose and treat patients who suffer from the devastating disorder. U-M's scientists and doctors study human cells to better understand how they are involved in the progressive scarring of the lungs. In addition, clinical testing is used to help better predict the stage of disease and the rate of progression in advising patients for therapy.

"The approach taken by our group really highlights the advantages of translational research in a complex human disease and shows the bench-to-bedside model is really a two-way street," notes Cory M. Hogaboam, Ph.D., a professor of pathology at U-M and the study's other senior investigator.


'/>"/>

Contact: Ian Demsky
idemsky@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
2. A new indicator of poor prognosis in node-negative colorectal cancer patients
3. Recurrence of breast cancer after more than 10 years is an important indicator of survival
4. Definitive diabetes indicator deceptively high in African-American children
5. 3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution
6. Study finds respiratory symptoms more reliable indicator of H1N1, not fever alone
7. Visual pattern preference may be indicator of autism in toddlers
8. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
9. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
10. Highmark Foundation Awards $120,000 to the American Heart Association
11. Stuttering Foundation Hails New Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... software products, today announced a strategic partnership with Lucidworks , the company ... and analyze their Fusion platform for building powerful enterprise search applications. , Element ...
(Date:1/24/2017)... ... 2017 , ... The Cruise Web Inc. was recognized today as ... Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships Awards ... based on overall business growth in revenue and guests and continuous partnership support and ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... that its annual Solutions Series of webinars will start January 31 with a ... a number of current health and benefits topics, including employee engagement, pricing transparency, ...
(Date:1/24/2017)... Rancho Santa Margarita, CA (PRWEB) , ... January 24, 2017 , ... ... career advancement platform for 21st century leadership, has named Hector M. Chavez, Manager, Employee ... cancer and diabetes treatment center - as its Hispanic Leader of the Month. City ...
(Date:1/24/2017)... Boston, MA (PRWEB) , ... January 24, 2017 ... ... What They Really Need to Thrive , Well-meaning studies such as the Fordham ... and schools can better serve top students, such as including gifted or high-achieving ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... and PUNE, India , January ... published by Allied Market Research, titled, "Cold Chain Logistics ... Confectionary, Dairy & Frozen Dessert, Meat, Fish & Sea ... Analysis and Industry Forecasts, 2014-2022," projects that the global ... million by 2022, growing at a CAGR of 16% ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, ... the Public today recognized 40 finalists in the Regeneron ... science and math competition for high school seniors. Finalists ... potential of their research projects. The finalists ... from March 9-15 to undergo a rigorous judging ...
(Date:1/24/2017)... -- Research and Markets has announced the addition of ... Material - Forecast to 2025" report to their offering. ... The Global Implantable ... around 5.4% over the next decade to reach approximately $54.28 billion ... market is witnessing include 3D medical printing is expected to develop ...
Breaking Medicine Technology: